• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

灯盏花素单层脂质体在兔体内的制备及药代动力学研究

Preparation and pharmacokinetics in rabbits of breviscapine unilamellar vesicles.

作者信息

Lv Wenli, Guo Jianxin, Li Jin, Wang Xueliang, Li Jianying, Ping Qineng

机构信息

School of Pharmacy, China Pharmaceutical University, Nanjing, PR China.

出版信息

Drug Dev Ind Pharm. 2006 Mar;32(3):309-14. doi: 10.1080/03639040500518880.

DOI:10.1080/03639040500518880
PMID:16556535
Abstract

The purpose of the study was to prepare the unilamellar liposomal vesicles of breviscapine (Breviscapine-LUVs) and investigate the pharmacokinetics of Breviscapine-LUVs in rabbits. Breviscapine-LUVs were prepared by the film dispersion method and treated further by extrusion. Its size distribution and zeta potential were determined by photon correlation spectroscopy. The encapsulation efficiency (EE) and cumulative release of Breviscapine-LUVs were assayed by the dialysis method. The crossover design (two periods) was used in six rabbits, which were administered Breviscapine-LUVs and reference preparation. Results showed that the particle size of Breviscapine-LUVs was 50.8 nm, and the polydispersity index was 0.287. The zeta potential was -24 mV +/- 9 mV (n = 3), and the EE% was 81.1 +/- 1.1% (n = 3). The cumulative release of vesicles in 0.9% NaCl was 17.2 +/- 0.78%, 26.1 +/- 0.68%, and 29.9 +/- 0.81% in 2, 8, and 24 h, respectively. The mean concentration-time curves of breviscapine liposomes and reference preparation were both fitted to a two-compartment model with the main pharmacokinetic parameters as follows: t(1/2beta) of Breviscapine-LUVs and reference preparation were (42.5 +/- 28.6) min and (6.01 +/- 4.64) min, respectively; CL((s)) were (15.3 +/- 9.03) mL x min(-1) and (84.6 +/- 40.6) mL x min(-1), respectively; AUC(0-300) were (1267 +/- 1083) microg x min x mL(-1) and (196 +/- 107) microg x min x mL(-1), respectively. Compared with the reference preparation, breviscapine liposomes had a much higher concentration in plasma and contained characteristic of sustained-release, which ameliorated the pharmacokinetic properties of scutellarin.

摘要

本研究的目的是制备灯盏花素单层脂质体囊泡(灯盏花素 - LUVs),并研究灯盏花素 - LUVs在兔体内的药代动力学。采用薄膜分散法制备灯盏花素 - LUVs,并通过挤压进一步处理。通过光子相关光谱法测定其粒径分布和zeta电位。采用透析法测定灯盏花素 - LUVs的包封率(EE)和累积释放率。采用交叉设计(两个周期)对6只兔进行实验,分别给予灯盏花素 - LUVs和参比制剂。结果显示,灯盏花素 - LUVs的粒径为50.8 nm,多分散指数为0.287。zeta电位为 -24 mV ± 9 mV(n = 3),EE%为81.1 ± 1.1%(n = 3)。囊泡在0.9%氯化钠中的累积释放在2、8和24 h分别为17.2 ± 0.78%、26.1 ± 0.68%和29.9 ± 0.81%。灯盏花素脂质体和参比制剂的平均浓度 - 时间曲线均符合二室模型,主要药代动力学参数如下:灯盏花素 - LUVs和参比制剂的t(1/2β)分别为(42.5 ± 28.6) min和(6.01 ± 4.64) min;CL(s)分别为(15.3 ± 9.03) mL·min⁻¹和(84.6 ± 40.6) mL·min⁻¹;AUC(0 - 300)分别为(1267 ± 1083) μg·min·mL⁻¹和(196 ± 107) μg·min·mL⁻¹。与参比制剂相比,灯盏花素脂质体在血浆中的浓度更高,具有缓释特性,改善了灯盏乙素的药代动力学性质。

相似文献

1
Preparation and pharmacokinetics in rabbits of breviscapine unilamellar vesicles.灯盏花素单层脂质体在兔体内的制备及药代动力学研究
Drug Dev Ind Pharm. 2006 Mar;32(3):309-14. doi: 10.1080/03639040500518880.
2
[Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs].灯盏花素脂质体在比格犬静脉注射后的药代动力学
Yao Xue Xue Bao. 2006 Jan;41(1):24-9.
3
Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats.灯盏花素脂质体在犬、兔和大鼠体内的比较药代动力学
Int J Pharm. 2008 Jul 9;359(1-2):118-22. doi: 10.1016/j.ijpharm.2008.03.047. Epub 2008 Apr 11.
4
Distribution of liposomal breviscapine in brain following intravenous injection in rats.大鼠静脉注射后灯盏花素脂质体在脑中的分布。
Int J Pharm. 2005 Dec 8;306(1-2):99-106. doi: 10.1016/j.ijpharm.2005.09.012. Epub 2005 Nov 8.
5
Preparation, characterization, and biodistribution of breviscapine proliposomes in heart.灯盏花素前体脂质体在心脏中的制备、表征及生物分布
J Drug Target. 2009 Jun;17(5):408-14. doi: 10.1080/10611860902913380.
6
[Pharmacokinetics of breviscapine in dogs and rabbits following single intravenous administration].灯盏花素单次静脉注射后在犬和兔体内的药代动力学
Zhong Yao Cai. 2005 Oct;28(10):913-6.
7
Characterization, biodistribution and targeting evaluation of breviscapine lipid emulsions following intravenous injection in mice.灯盏花素脂肪乳注射液在小鼠体内的特征描述、生物分布及靶向评价
Drug Deliv. 2011 Feb;18(2):159-65. doi: 10.3109/10717544.2010.528068. Epub 2010 Oct 28.
8
Optimized preparation, characterization and biodistribution in heart of breviscapine lipid emulsion.灯盏花素脂质体的优化制备、表征及其在心脏中的生物分布
Chem Pharm Bull (Tokyo). 2010 Nov;58(11):1455-60. doi: 10.1248/cpb.58.1455.
9
Enhanced oral bioavailability of breviscapine after encapsulation in a liposomal formulation.灯盏花素脂质体制剂包封后口服生物利用度提高。
Pharmazie. 2005 Jun;60(6):475-6.
10
Study on pharmacokinetics of scutellarin in rabbits.灯盏花素在兔体内的药代动力学研究。
Yao Xue Xue Bao. 2003 Oct;38(10):775-8.

引用本文的文献

1
Pharmacokinetics study of ginsenoside Rg1 liposome by pulmonary administration.人参皂苷Rg1脂质体经肺部给药的药代动力学研究
Heliyon. 2024 Apr 26;10(9):e29906. doi: 10.1016/j.heliyon.2024.e29906. eCollection 2024 May 15.
2
Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy.设计构建吐温 60@2β-CD 自组装囊泡作为癌症化疗的药物传递载体。
Drug Deliv. 2018 Nov;25(1):623-631. doi: 10.1080/10717544.2018.1440448.
3
Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine.
基于离子复合物的纳米结构化脂质载体的开发,以改善灯盏花乙素的药代动力学特征。
Acta Pharmacol Sin. 2013 Aug;34(8):1108-15. doi: 10.1038/aps.2013.43. Epub 2013 Jun 17.